Should sponsors and dsmbs share interim results across trials?

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 5, 2011, Pages 433-435

  Shah, Seema K ^a   Dawson, Liza ^b   Dixon, Dennis O ^a   Lie, Reidar K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Research Ethics Team   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; ZIDOVUDINE;

ADVERSE OUTCOME; ARTIFICIAL MILK; BREAST FEEDING; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; DEVELOPING COUNTRY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANTILE DIARRHEA; INFECTION; INFECTION PREVENTION; INFECTION RISK; INFORMATION DISSEMINATION; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL LITERATURE; NATIONAL HEALTH ORGANIZATION; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; VERTICAL TRANSMISSION; WATER AVAILABILITY; WATER QUALITY;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; CONFIDENTIALITY; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERINSTITUTIONAL RELATIONS; NEVIRAPINE; PREGNANCY; ZIDOVUDINE;

EID: 81755174329     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318236eca3     Document Type: Review

References (23)

1. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nature Rev Drug Discovery. 2008;7:13-14.
2. Zink A, Silman AJ. Ethical and legal constraints on data sharing between countries in multinational epidemiological studies in Europe report from a joint workshop of the European league against rheumatism standing committee on epidemiology with the "Auto Cure" project. Ann Rheum Dis. 2008;67:1041-1043. (Pubitemid 351956672)
3. Hillman DW, Louis TA. DSMB case study: decision making when a similar clinical trial is stopped early. Control Clin Trials. 2003;24:85-91. (Pubitemid 36135950)
4. Fisher L, Klibaner M. Regulatory issues for data and safety monitoring committees. Am Heart J. 2001;141:536-541. (Pubitemid 32260717)
5. Lavery JV, Singer PA, Ridzon R, et al. In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs? PLoS Med. 2009;6:4-7.
6. World Health Organization. Acceptable medical reasons for the use of breast-milk substitutes. 2009. Available at: http://whqlibdoc.who.int/hq/2009/ WHO-FCH-CAH-09.01-eng.pdf. Accessed November 20, 2009.
7. Morreim EH. Medical research litigation and malpractice tort doctrines: courts on a learning curve. 4 Hous. J. Health L. & Pol'y. 2004;4:1-86.
8. Fleming TR, Sharples K, McCall J, et al. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials. 2008;5: 157-167. (Pubitemid 351682525)
9. NIH Policy for Data and Safety Monitoring Available at: http://grants. nih.gov/grants/guide/notice-files/not98-084.html. Accessed June 10
10. 1998. Further guidance on a data and safety monitoring for phase I and phase II trials. Available at: http://grants.nih.gov/grants/guide/notice-files/ not-od-00-038.html. Accessed June 5, 2000 (last visited June 9, 2011).
11. Food and Drug Administration. Department of Health and Human Services. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees, non-binding recommendations OMB Control No. 0910-0581. 2006. Available at: http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm127073.pdf. Accessed June 9, 2011.
12. Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: Issues and controversies regarding confidentiality. Stat Med. 2002;21:2843-2851.
13. Armitage P. Delta data and safety monitoring committee, data and safety monitoring in the delta trial. Control Clin Trials. 1999;20:229-241. (Pubitemid 29219503)
14. Marmor MF. A randomized trial of Vitamin A and Vitamin E supplementation for retinitis pigmentosa. Arch Opthalmol. 1993;111: 1460-1461.
15. Norton EW. A randomized trial of Vitamin A and Vitamin E supplementation for retinitis pigmentosa. Arch Opthalmol. 1993;111:1460.
16. Sydes MR, Spiegelhalter DJ, Altman DG, et al. DAMOCLES Group. Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials. 2004;1:60-79.
17. Pocock SJ, Hughes MD. Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials. 1989;10(4 suppl): 209S-221S. (Pubitemid 20029387)
18. PLoS Medicine, editorial and publishing policies. Available at: http://www.plosmedicine.org/static/policies.action#copyright. Accessed May 12, 2010.
19. The Lancet, Information for Authors. Available at: http://download. thelancet. com/flatcontentassets/authors/lancet-information-for-authors.pdf. Accessed June 9, 2011.
20. Lilford RJ, Braunholtz D, Edwards S, et al. Monitoring clinical trials-interim data should be publicly available. BMJ. 2001;323:441-442. (Pubitemid 32801403)
21. Wells RJ, Gartside PS, McHenry CL. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees. IRB. 2000;22:7-11.
22. Miller FG, Wendler D. Is it ethical to keep interim findings of randomized controlled trials confidential? J Med Ethics. 2008;34:198-201.
23. Dixon DO, Lagakos SW. Should data and safety monitoring boards share confidential interim data? Control Clin Trials. 2000;21:1-6. (Pubitemid 30047054)